

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

00 FEB 14 AM 11:03

H.D.

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported 1333 New Hampshire Avenue, NW			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country): DC 20036			
4. Contact Name Daniel L. Spiegel	Telephone 202-887-4000	E-mail (optional)	5. Senate ID # 682-1406
7. Client Name <input type="checkbox"/> Self Biotechnology Industry Organization	6. House ID # 31784134		

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ → Termination Date \_\_\_\_\_ 11. No Lobbying Activity ☐

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> → \$ <u>20,000</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> → \$ _____ Income (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input type="checkbox"/> Method A. Reporting amounts using LDA definitions only	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	

Signature \_\_\_\_\_

Printed Name and Title Daniel L. Spiegel, Partner

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Participation in international negotiations concerning international trade in pharmaceutical products of biotechnology

17. House(s) of Congress and Federal Agencies contacted ☐ Check if None

U.S. Department of Agriculture  
U.S. Department of State  
Office of the Vice President  
Council on Environmental Quality  
Office of the U.S. Trade Representative  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Laura M. Reifschneider		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature \_\_\_\_\_ Date February 14, 2000

Printed Name and Title Daniel L. Spiegel, Partner

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

Participation in international negotiations concerning international trade in pharmaceutical products of biotechnology


17. House(s) of Congress and Federal Agencies contacted ☐ Check if None

U.S. Department of Agriculture  
U.S. Department of State  
Council on Environmental Quality  
Office of the Vice President  
Office of the U.S. Trade Representative  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Laura M. Reifschneider		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature  Date February 14, 2000  
Printed Name and Title Daniel L. Spiegel, Partner